Positive Impact of Blue Light Cystoscopy on Recurrence in Bladder Cancer Presented at the Annual SUO Meeting
Photocure ASA, The Bladder Cancer Company, announces that new evidence was presented at the 22nd Annual Society of Urologic Oncology (SUO) meeting demonstrating that Blue Light Cystoscopy (BLC®) decreases the risk and prolongs time to recurrence based on Real World Evidence from the U.S. multi-institutional Blue Light Cystoscopy with Cysview® Registry database.
This large, prospective, longitudinal, multisite registry collects data on NMIBC* patients who have undergone transurethral resection of bladder tumor (TURBT) using Blue Light as an adjunct to white light cystoscopy (WLC). The new data represent an interim analysis of the study, which is projected to enroll 4,400 patients in total. In this study, all registry patients analyzed (n=2055) received Blue Light. They were directly compared to a historical White-Light (WL)-only control group (n=261) of similar age, stage, grade, and clinical management (i.e., intravesical therapy).
Kaplan-Meier curves demonstrate recurrence-free survival (RFS) for BLC patients compared to a WL-only arm with a mean follow up of 27.4 months for BLC and 53 months for the historical WL control arm. The overall risk of recurrence was significantly lower following BLC compared to WLC alone (Hazard Ratio (HR) 0.33; 95% Confidence Interval (CI) 0.28-0.40, p-value=0<.0001). Authors indicate that the lower incidence of recurrence in the BLC arm were durable, as rates tracked over 5 years consistently out-performed WLC in the historical control group.
The data were presented at the Annual Meeting of the Society of Urologic Oncology meeting held November 30 – December 2, 2022, in San Diego, USA. The SUO is a congress led by internationally renowned urologic oncologists, medical oncologists, and scientists on topics of genitourinary medicine such as bladder, kidney, and prostate cancer. This year, Photocure has continued to partner with KARL STORZ with a joint exhibit featuring the new blue light SAPHIRA™ system, as well as information on flexible blue light.
“These real-world data from our U.S. Cysview Registry emphasize that better tumor detection and more complete resection using BLC can translate into more favorable long-term patient outcomes,” said Geoff Coy Vice President and General Manager, North America. “Interest in integrating BLC into the management of bladder cancer is high among practicing urologists, and many stopped by the exhibit at SUO to see the SAPHIRA demonstration unit on display and get hands-on experience with the upgraded system for TURBT procedures. SAPHIRA became commercially available in late September 2022, and we believe that the new system is helping to expand the use of BLC so that more patients diagnosed with bladder cancer have access to the benefits of enhanced cystoscopy.”
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more